Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1813MR)

This product GTTS-WQ1813MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1813MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13532MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ9755MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ3085MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ5537MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ15947MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9075MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ13923MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ6860MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DX-2930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW